Compare Cytokinetics Inc (CYTK) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Nu Holdings Ltd — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Nu Holdings Ltd trades at $13.65 (market cap $66.85B). The key difference: Nu Holdings Ltd is far larger — about 6.2× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CYTK | NU | |
|---|---|---|
Market Cap | $10.78B | $66.85B |
Sector | Technology | Financials |
52-Week High | $87.26 | $18.76 |
52-Week Low | $33.23 | $11.60 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Nu Holdings (NU) trades at $13.84, down 1.98% with a bearish technical outlook. The company shows strong fundamental growth with revenue increasing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Recent earnings show mixed results with two misses but a beat in Q3 2025. Analyst consensus remains bullish with a $14.98 price target despite recent price weakness.
Nu presents a compelling growth story with expanding profitability and market position in Latin American banking. Key risks include unsecured credit exposure and regional economic volatility. The current valuation at 21.35 P/E offers potential upside if the company maintains its growth trajectory and executes on expansion plans in Brazil and Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
